The high expression of CHD4 was significantly associated with pre-treatment (pre-Tx) tumor status (T3–T4 versus T1–T2; p < 0.001), pre-Tx lymph node metastasis (N1–2 versus N0; p < 0.001), post-treatment (post-Tx) tumor status (T3-T4 versus T1-T2; p < 0.001), post-Tx lymph node metastasis (N1–2 versus N0; p < 0.001), vascular invasion (p = 0.042), and tumor regression grade (p = 0.001). Here, CHD4 is linked to metastatic malignant neoplasm in the lymph nodes.